The generic injectable market would grow at a CAGR of 14.1% over the predicted time frame. The market is expected to increase in value from US$ 107.6 Bn in 2022 to US$ 309.1Bn in 2030.
The on generic injectable Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2180
Report Scope of the Generic Injectable Market
| Report Coverage | Details |
| Market Size in 2022 |
USD 107.6 Billion |
| Market Size by 2030 |
USD 309.1 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 14.1% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product Type, Molecular Type, Application, Administration, Distribution Channel, and Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Generic injectable Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Generic injectable market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Generic injectable market are included as given below:
Generic injectable Market Key Players
- DR. Reddys Laboratries Ltd
- Baxter International
- Mylan N.A
- Teva Pharmaceuticals
- Astra Zeneca Plc
- Sanofi S.A
- Fresenius Kabi
- Pfizer Inc
- Cipla Ltd
- Merck & Co. Inc
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Limited
- Samsung Biologics Co Ltd
- Biocon
- Lupin,Ltd
- Astrazeneca
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Cosette Pharmaceutical, Inc
- Johnson & Johnson Services, Inc
- Sanofi SA
- Amgen Inc.
- Bristol- Myers Squibb Company
- Piramal Pharma Solutions
- Merck KGaA
Market Segments
By Product Type
- Chemotherapy agents
- Small molecule antibiotics
- Vaccines
- Peptide antibiotics
- Blood factors
- Peptide hormone
- Insulin
- Cytokines
- Immunoglobin
- Monoclonal Antibodies
By Molecular Type
- Small Molecule
- Large Molecule
By Application
- Oncology
- Diabetes
- Infectious Diseases
- Blood Disorders
- Musculoskeletal Disorders
- Hormonal Disorders
- Pain Management
- CNS Diseases
- Cardiovascular Diseases
By Administration
- Intravenous (IV)
- Intramuscular (IM)
- Subcutaneous (SC)
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global generic injectable market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the generic injectable market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generic Injectable Market
5.1. COVID-19 Landscape: Generic Injectable Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generic Injectable Market, By Product Type
8.1. Generic Injectable Market, by Product Type, 2022-2030
8.1.1. Chemotherapy agents
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Small molecule antibiotics
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Peptide antibiotics
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Blood factors
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Peptide hormone
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Insulin
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Cytokines
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Immunoglobin
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Monoclonal Antibodies
8.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Generic Injectable Market, By Molecular Type
9.1. Generic Injectable Market, by Molecular Type, 2022-2030
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Generic Injectable Market, By Application
10.1. Generic Injectable Market, by Application, 2022-2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Blood Disorders
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Musculoskeletal Disorders
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Hormonal Disorders
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Pain Management
10.1.7.1. Market Revenue and Forecast (2017-2030)
10.1.8. CNS Diseases
10.1.8.1. Market Revenue and Forecast (2017-2030)
10.1.9. Cardiovascular Diseases
10.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Generic Injectable Market, By Administration
11.1. Generic Injectable Market, by Administration, 2022-2030
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Intramuscular (IM)
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Intramuscular (IM)
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Generic Injectable Market, By Distribution Channel
12.1. Generic Injectable Market, by Distribution Channel, 2022-2030
12.1.1. Hospital pharmacy
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Hospital pharmacy
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Drug stores
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Online pharmacy
12.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Generic Injectable Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.7. Market Revenue and Forecast, by Administration (2017-2030)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.10. Market Revenue and Forecast, by Administration (2017-2030)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. DR. Reddys Laboratries Ltd
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Baxter International
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Mylan N.A
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Teva Pharmaceuticals
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Teva Pharmaceuticals
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sanofi S.A
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Fresenius Kabi
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Cipla Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co. Inc
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments